|Application ||WB, IHC|
|Calculated MW||50688 Da|
|Other Names||Chromogranin-A, CgA, Pituitary secretory protein I, SP-I, Vasostatin-1, Vasostatin I, Vasostatin-2, Vasostatin II, EA-92, ES-43, Pancreastatin, SS-18, WA-8, WE-14, LF-19, AL-11, GV-19, GR-44, ER-37, CHGA|
|Target/Specificity||A synthetic peptide corresponding to residues near the C-terminus of human Chromogranin A was used as an immunogen.|
|Format||50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||Chromogranin-A Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Pancreastatin: Strongly inhibits glucose induced insulin release from the pancreas. Serpinin: Regulates granule biogenesis in endocrine cells by up-regulating the transcription of protease nexin 1 (SERPINE2) via a cAMP-PKA-SP1 pathway. This leads to inhibition of granule protein degradation in the Golgi complex which in turn promotes granule formation.|
|Cellular Location||Cytoplasmic vesicle, secretory vesicle lumen. Cytoplasmic vesicle, secretory vesicle membrane. Secreted. Note=Associated with the secretory granule membrane through direct interaction to SCG3 that in turn binds to cholesterol-enriched lipid rafts in intragranular conditions.|
|Tissue Location||GE-25 is found in the brain.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Chromogranin A (CgA) is an 86 kDa protein that is the major member of the granin family of acidic secretory glycoproteins located in neuroendocrine cells. CgA is believed to play a role in targeting peptide hormones and neurotransmitters to granules of the regulated pathways and inhibit hormone and neurotransmitter release (1). Also, the widespread distribution of CgA has made the measurement of circulating immunoreactive CgA a valuable tool in the diagnosis of neuroendocrine neoplasia, and CgA immunohistochemistry can help to identify the neuroendocrine nature of tumors. The N-terminal domain of CgA inhibits tumor necrosis factor α (TNFα) induced gap formation in human umbilical venous endothelial cells (2). CgA levels which reflect neuroendocrine differentiation of prostatic carcinoma may have a diagnostic, therapeutic and prognostic role in the management of prostate cancer patients (3).
1. Hendy GN, et al. Clin Invest Med 18(1):47-65, 1995
2. Blois A, et al. Regul Pept 135(1-2):78-84, 2006
3. Leibovitch I, et al. Harefuah 145(1):25-9, 2006
If you have any additional inquiries please email technical services at email@example.com.